Navigation Links
Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
Date:10/7/2009

EAST BRUNSWICK, N.J., Oct. 7 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today its intention to commence, subject to market and other conditions, an underwritten public offering of 4,000,000 shares of its common stock pursuant to an effective shelf registration statement on Form S-3. Savient also intends to grant the underwriters a 30-day option to purchase up to an aggregate of 600,000 additional shares of common stock to cover over-allotments, if any. All of the shares in the offering are to be sold by Savient. J.P. Morgan Securities Inc. is acting as sole book-running manager of the proposed offering. Wedbush PacGrow Life Sciences is also acting as a lead manager of the proposed offering.

Savient intends to use the net proceeds from this offering to complete its effort to seek FDA approval of KRYSTEXXA(TM) (pegloticase), to develop a program of regulatory filings and review of KRYSTEXXA in other countries, to engage a global secondary source supplier and a secondary fill and finish manufacturer for pegloticase, and for working capital and other general corporate purposes.

A shelf registration statement on Form S-3 relating to the shares was filed with the Securities and Exchange Commission on September 24, 2007 and became effective on October 10, 2007. Information about the offering is available in the preliminary prospectus supplement to be filed with the Securities and Exchange Commission. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

Copies of the preliminary prospectus supplement and accompanying prospectus may be obtained by contacting J.P. Morgan Securities Inc., Attention: Prospectus Department, 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing KRYSTEXXA(TM) (pegloticase) for the treatment of chronic gout in patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly referred to as Puricase(R), from Duke University and Mountain View Pharmaceuticals, Inc. Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the U.S. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc.

SVNT -G

SOURCE Savient Pharmaceuticals, Inc.


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
2. Savient Provides Update on Pegloticase BLA
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... January 13, 2017 Constant research ongoing ... will collectively contribute to the demand for western blotting technique. ... value of US$ 551.0 Mn by 2016 end. Developing economies ... most lucrative markets for western blotting, whereas North ... ...
(Date:1/13/2017)... MURRIETA, Calif. , Jan. 13, 2017  Alfalfa, cattle, ... COPAN Diagnostic,s new environmental sampling film , which emphasizes the ... video, released today, highlights how COPAN,s ... product that simplifies the surface sampling process in the wake ... . In addition, COPAN is expanding ...
(Date:1/13/2017)... -- This morning, Stock-Callers.com draws attention to ... at yesterday,s closing bell: Clovis Oncology Inc. (NASDAQ: ... GALE ), and ACADIA Pharmaceuticals Inc. (NASDAQ: ... to develop technologies and products that combat debilitating and ... use less and cleaner energy, and provide safer, cleaner ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... 16, 2017 , ... Date aired: January 9, 2017 , ... Kleyne, America’s leading water educator, researcher and advocate welcomed health activist, author, science ... Kleyne Hour Power of Water, Global Climate Change and Your Health on Voice ...
(Date:1/16/2017)... , ... January 16, 2017 , ... One thing common ... to treat, but to test for, as well. The money spent screening for and ... Doctors in the U.S. screen patients for cancer more than in any other country ...
(Date:1/16/2017)... WA (PRWEB) , ... January 16, 2017 , ... NexTec ... 2016, a group of 100 organizations honored for their accomplishments in the field of ... such growth, industry leadership and recognition, and innovation. Selection is not based on revenue ...
(Date:1/15/2017)... , ... January 15, 2017 , ... Whole Health Supply, LLC is announcing the release ... are also new avenues for purchase. , The 2017 edition has wide jaws that ... for the older boomers as well as diabetics. This handle is reinforced for extra strength ...
(Date:1/15/2017)... ... January 15, 2017 , ... ... physicians in eight Bay Area counties for 2017. Almost 1,000 nominations were submitted ... managing the award process. Results were announced the magazine’s January 2017 issue ...
Breaking Medicine News(10 mins):